File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis

TitleOpen Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis
Authors
Keywordspublic-private partnership
pharmaceutical industry
drug discovery
patient-centered innovation
intellectual property
Issue Date2021
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology
Citation
Frontiers in Pharmacology, 2021, v. 11, p. article no. 587526 How to Cite?
AbstractOpen innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining social media attention remains largely unexplored. The scientific literature of open innovation was examined by means of bibliometric analyses to identify the most prolific authors, organizations, countries, journals, research areas, and recurring terms. By accessing the Web of Science Core Collection and Altmetric electronic databases, citation-related and Altmetric data were evaluated. Public-private partnerships and a selection of newly introduced potential novel drugs in the analyzed publications were identified. North America and Europe were the major literature contributors. Research outputs were mainly published in journals focused on business and economics, pharmacology and pharmacy, and engineering. Many pharmaceutical and biotechnological companies contributed to the analyzed publications, with higher mean citation counts and social media attention (Altmetric score) than nonindustry articles. Public-private partnerships fostered financial support, sharing of expertise and intellectual property, and research collaborations. In summary, open innovation might serve as a powerful strategy to both benefit the involved industry entities and accelerate the development of solutions and products for the betterment of human health.
Persistent Identifierhttp://hdl.handle.net/10722/295513
ISSN
2023 Impact Factor: 4.4
2023 SCImago Journal Rankings: 1.066
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYeung, AWK-
dc.contributor.authorAtanasov, AGA-
dc.contributor.authorSheridan, H-
dc.contributor.authorKlager, E-
dc.contributor.authorEibensteiner, F-
dc.contributor.authorVölkl-Kernsock, S-
dc.contributor.authorKletecka-Pulker, M-
dc.contributor.authorWillschke, H-
dc.contributor.authorSchaden, E-
dc.date.accessioned2021-01-25T11:15:57Z-
dc.date.available2021-01-25T11:15:57Z-
dc.date.issued2021-
dc.identifier.citationFrontiers in Pharmacology, 2021, v. 11, p. article no. 587526-
dc.identifier.issn1663-9812-
dc.identifier.urihttp://hdl.handle.net/10722/295513-
dc.description.abstractOpen innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining social media attention remains largely unexplored. The scientific literature of open innovation was examined by means of bibliometric analyses to identify the most prolific authors, organizations, countries, journals, research areas, and recurring terms. By accessing the Web of Science Core Collection and Altmetric electronic databases, citation-related and Altmetric data were evaluated. Public-private partnerships and a selection of newly introduced potential novel drugs in the analyzed publications were identified. North America and Europe were the major literature contributors. Research outputs were mainly published in journals focused on business and economics, pharmacology and pharmacy, and engineering. Many pharmaceutical and biotechnological companies contributed to the analyzed publications, with higher mean citation counts and social media attention (Altmetric score) than nonindustry articles. Public-private partnerships fostered financial support, sharing of expertise and intellectual property, and research collaborations. In summary, open innovation might serve as a powerful strategy to both benefit the involved industry entities and accelerate the development of solutions and products for the betterment of human health.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology-
dc.relation.ispartofFrontiers in Pharmacology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectpublic-private partnership-
dc.subjectpharmaceutical industry-
dc.subjectdrug discovery-
dc.subjectpatient-centered innovation-
dc.subjectintellectual property-
dc.titleOpen Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis-
dc.typeArticle-
dc.identifier.emailYeung, AWK: ndyeung@hku.hk-
dc.identifier.authorityYeung, AWK=rp02143-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fphar.2020.587526-
dc.identifier.pmid33519448-
dc.identifier.pmcidPMC7840485-
dc.identifier.scopuseid_2-s2.0-85101976604-
dc.identifier.hkuros320998-
dc.identifier.volume11-
dc.identifier.spagearticle no. 587526-
dc.identifier.epagearticle no. 587526-
dc.identifier.isiWOS:000612205700001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats